Tags

Type your tag names separated by a space and hit enter

Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei.
J Antimicrob Chemother. 2005 Jun; 55(6):1029-31.JA

Abstract

OBJECTIVES

Trimethoprim/sulfamethoxazole is commonly used to treat melioidosis. Antimicrobial susceptibility testing using the disc diffusion method is commonly used in melioidosis-endemic areas, but may overestimate resistance to trimethoprim/sulfamethoxazole.

PATIENTS AND METHODS

We performed disc diffusion and Etest on isolates from the first positive culture for all patients presenting to Sappasithiprasong Hospital, Ubon Ratchathani, Thailand, with culture-confirmed melioidosis between 1992 and 2003.

RESULTS

The estimated resistance rate for 1976 clinical Burkholderia pseudomallei isolates was 13% by Etest and 71% by disc diffusion. All isolates classed as either susceptible (n=358) or as having intermediate resistance (n=218) on disc diffusion were susceptible by Etest. Only 258 of the 1400 (18%) isolates classed as resistant on disc diffusion were resistant by Etest.

CONCLUSIONS

Disc diffusion testing of B. pseudomallei may be useful as a limited screening tool in resource poor settings. Isolates assigned as 'susceptible' or 'intermediate' by disc diffusion may be viewed as 'susceptible'; those assigned as 'resistant' require further evaluation by MIC methodology.

Authors+Show Affiliations

Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15886263

Citation

Wuthiekanun, Vanaporn, et al. "Trimethoprim/sulfamethoxazole Resistance in Clinical Isolates of Burkholderia Pseudomallei." The Journal of Antimicrobial Chemotherapy, vol. 55, no. 6, 2005, pp. 1029-31.
Wuthiekanun V, Cheng AC, Chierakul W, et al. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J Antimicrob Chemother. 2005;55(6):1029-31.
Wuthiekanun, V., Cheng, A. C., Chierakul, W., Amornchai, P., Limmathurotsakul, D., Chaowagul, W., Simpson, A. J., Short, J. M., Wongsuvan, G., Maharjan, B., White, N. J., & Peacock, S. J. (2005). Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. The Journal of Antimicrobial Chemotherapy, 55(6), 1029-31.
Wuthiekanun V, et al. Trimethoprim/sulfamethoxazole Resistance in Clinical Isolates of Burkholderia Pseudomallei. J Antimicrob Chemother. 2005;55(6):1029-31. PubMed PMID: 15886263.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. AU - Wuthiekanun,Vanaporn, AU - Cheng,Allen C, AU - Chierakul,Wirongrong, AU - Amornchai,Premjit, AU - Limmathurotsakul,Direk, AU - Chaowagul,Wipada, AU - Simpson,Andrew J H, AU - Short,Jennifer M, AU - Wongsuvan,Gumphol, AU - Maharjan,Bina, AU - White,Nicholas J, AU - Peacock,Sharon J, Y1 - 2005/05/10/ PY - 2005/5/12/pubmed PY - 2005/9/16/medline PY - 2005/5/12/entrez SP - 1029 EP - 31 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 55 IS - 6 N2 - OBJECTIVES: Trimethoprim/sulfamethoxazole is commonly used to treat melioidosis. Antimicrobial susceptibility testing using the disc diffusion method is commonly used in melioidosis-endemic areas, but may overestimate resistance to trimethoprim/sulfamethoxazole. PATIENTS AND METHODS: We performed disc diffusion and Etest on isolates from the first positive culture for all patients presenting to Sappasithiprasong Hospital, Ubon Ratchathani, Thailand, with culture-confirmed melioidosis between 1992 and 2003. RESULTS: The estimated resistance rate for 1976 clinical Burkholderia pseudomallei isolates was 13% by Etest and 71% by disc diffusion. All isolates classed as either susceptible (n=358) or as having intermediate resistance (n=218) on disc diffusion were susceptible by Etest. Only 258 of the 1400 (18%) isolates classed as resistant on disc diffusion were resistant by Etest. CONCLUSIONS: Disc diffusion testing of B. pseudomallei may be useful as a limited screening tool in resource poor settings. Isolates assigned as 'susceptible' or 'intermediate' by disc diffusion may be viewed as 'susceptible'; those assigned as 'resistant' require further evaluation by MIC methodology. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/15886263/Trimethoprim/sulfamethoxazole_resistance_in_clinical_isolates_of_Burkholderia_pseudomallei_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dki151 DB - PRIME DP - Unbound Medicine ER -